New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson
The Center will initially investigate KRAS pathway inhibitors and a TRAILR2 antibody from Boehringer Ingelheim’s cancer research
Ingelheim, Germany – Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.
The partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It further combines the unique patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division(link is external) with the innovative pipeline of novel medicines from Boehringer Ingelheim.
MD Anderson’s Therapeutics Discovery division is a multidisciplinary team of clinicians and researchers focused on advancing the next generation of cancer therapies. As part of the division, the TRACTION(link is external)(Translational Research to Advance Therapeutics and Innovation in Oncology) platform conducts cutting-edge translational research to better understand how new medicines work and which patients will see most benefit.